Murphy & Mullick Capital Management Corp Roivant Sciences Ltd. Transaction History
Murphy & Mullick Capital Management Corp
- $109 Billion
- Q4 2024
A detailed history of Murphy & Mullick Capital Management Corp transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Murphy & Mullick Capital Management Corp holds 100 shares of ROIV stock, worth $1,049. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$1,049% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
327Shares Held
506MCall Options Held
1.14MPut Options Held
1.26M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$692 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$690 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$567 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$462 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$371 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.39B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...